Phaseline

Targets › GPC2

GPC2 (Glypican-2 [Cleaved into: Secreted glypican-2]): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Cell surface proteoglycan that bears heparan sulfate. May fulfill a function related to the motile behaviors of developing neurons (By similarity). (UniProt, Q8N158)

Open in Phaseline: the race on GPC2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stanford UniversityGPC2-CAR T cells
Anti-GPC2 chimeric antigen receptor T cells
GPC2Phase 1MedulloblastomaAug 2027

Conditions

Medulloblastoma (1)

Modalities

mixed (1)

Companies

Stanford University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.